Silicon Labs Is a Pending $231 Buyout, Not a Fully Priced Growth Stock

Silicon Labs opened a new $23 million R&D lab in Austin this month, and the natural reading for shareholders is encouraging: the IoT chip designer is up roughly 68% this year, the lab supports a next-generation "Series 3" platform, and the second-quarter print looked strong. The reader is invited to ask whether the stock is expensive. That is the wrong question, because the stock is no longer being priced at all. It is being arbitraged.

The Takeover Reset the Price

In February, Texas Instruments agreed to buy Silicon Labs for $231 per share in cash, a total of about $7.5 billion and a premium of roughly 69% to the stock's last unaffected close. The equity is being retired at that price, and the market has simply pinned the shares just beneath it. Silicon Labs closed near $220 this week, within about 5% of the offer. The 68% annual gain is not a re-rating of the business. It is the deal premium plus interest in the short window left open.

This is not a valuation question in the normal sense. Multiples on trailing earnings barely apply when a buyer has named the price: trailing P/E is meaningless against a net loss, and the price-to-sales ratio of roughly 8.6 measures nothing the acquirer is paying for. TI is not buying Silicon Labs' current earnings — the company still loses money on a GAAP basis, posting a $(0.32) per-share loss in the June quarter even as non-GAAP EPS reached $0.71, up 545% year over year on $228 million of revenue. TI is paying a strategic premium for low-power wireless design and its software ecosystem. Whatever Silicon Labs' recovery is worth to a public-market buyer, the $231 figure already prices it.

What the Same Earnings Say Now

The operating results still matter, but only for what they say about the deal's risk, not the upside. Revenue rose 18% year over year to $228 million in the June quarter, with the Industrial & Commercial segment up 23% to $135 million. Bookings accelerated and distributor inventory fell. That is a genuine cyclical recovery off the bottom of a sharp downcycle.

None of it moves the share price much, because the price is already set. What the results reveal is that the company must keep running a complete, still-marginally-profitable business for more than a year before the buyer takes over. That is the real meaning of the Austin lab: it is not a bullish signal that management is betting on the standalone future. It is the cost of keeping the asset alive and competitive through a close that is not expected until the first half of 2027 — a disruption Silicon Labs has acknowledged by suspending forward guidance. The lab, at $23 million and partly funded by a Texas state grant, is requisition spending, the price of reaching the closing table in one piece. A company being bought for $231 per share does not stop investing; it can barely afford to slow down.

The One Gate That Matters Now

The spread between the $231 offer and the ~$220 market price is the market's estimate of the risk that the deal never closes, and the unresolved variable sits in Beijing. Silicon Labs derived 13% of its revenue from end customers in China on one recent filing, and 32% when measured by shipped-to location. A merger of a U.S. analog giant with a chip house earning a third of its revenue from China is precisely the kind of transaction that needs Chinese clearance, and that front has not moved.

As of this spring, China's antitrust regulator had not formally accepted the merger filing at all — a procedural stall that hangs over the whole timeline. This week brought a report that the regulator is moving the transaction to a longer phase-two review. Closed deals in China can take months, and the clearance can be withheld as leverage in a way the merger agreement does not price. TI's break fee if it walks is $499 million, a rounding error against the $7.5 billion purchase price, so the buyer is not locked in.

The arithmetic for a current shareholder is straightforward. At roughly $220, the upside to $231 is about $11 a share, under 5%, and that payout is not due until some point in the first half of 2027 — a low single-digit annualized return for holding a near-term cash claim. The downside is the reset to a going-concern value well below the offer if Chinese clearance stalls out or the buyer renegotiates. The recovery in booking and margins is real but does not backstop a $231 price in a world without the deal.

So the "fully priced" framing is not quite right. Silicon Labs is not overvalued on its own merits; it trades where it does because a buyer has agreed to pay $231 and the market is discounting the one thing standing in the way. The question for an investor is not whether the stock is expensive but whether under 5% over most of a year fairly compensates for an open-ended uncertainty controlled by a foreign regulator. The R&D lab is evidence the company expects to keep operating for a long time yet — which is, in effect, an admission that the close, and the payday, are still far away.